End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review

doi:10.5662/wjm.v4.i2.123

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4865)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-7) series.

Item

Count

PDF

295

WORD

250

HTML

2343

Tables (1-7)

235

Sum=3123

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

883

Download

859

Sum=1742

Jun 26, 2014 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Methodol. Jun 26, 2014; 4(2): 123-132
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.123

Table 6 Characteristics of randomized clinical trials including clinical response measures as the primary end point after first line medical treatment of metastatic castration-resistant prostate cancer

Trial	Arms	No. pts	Publication year	PROmeasure	Palliative response rate (%)
Canadian Trial[4]	MXN + PDN	80	1996	Palliative response (moore)	29¹
Canadian Trial[4]	PDN	81	1996	Palliative response (moore)	12
SIG-1 Trial[37]	SUR + HDC	228	2000	Palliative response (BPI + analgesics)	43¹
SIG-1 Trial[37]	Placebo + HDC	230	2000	Palliative response (BPI + analgesics)	28
NCIC PR06[35]	MXN + PDN + CLD	104	2003	Palliative response (moore)	46
NCIC PR06[35]	MXN + PDN + Placebo	105	2003	Palliative response (moore)	39

¹Statistically significant difference. BPI: Brief pain inventory; CLD: Clodronate; HDC: Hydrocortisone; MXN: Mitoxantrone; PDN: Prednisone; PRO: Patient-reported outcome; SUR: Suramine.

Citation: Colloca G, Venturino A, Governato I. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol 2014; 4(2): 123-132
URL: https://www.wjgnet.com/2222-0682/full/v4/i2/123.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i2.123